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Monitoring during Pediatric 
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A Review of Current issues
 
Lindsay M. Ryerson* and Laurence L. Lequier
Pediatric Critical Care, Stollery Children’s Hospital, Edmonton, AB, Canada
Anticoagulation is an imperfect science and is even more complicated in neonates and 
young children. The addition of the extracorporeal life support (ECLS) foreign circuit adds 
an additional layer of complexity. Anticoagulation goals during ECLS are to maintain a 
clot-free circuit and a hemostatically balanced patient. Unfractionated heparin (UFH) is 
the default gold standard anticoagulant as no large studies have been performed on any 
other anticoagulants. This review will focus on the advantages and disadvantages of 
the various methods to monitor UFH anticoagulation, discuss alternative anticoagulants, 
and examine bleeding and thrombotic complications during ECLS.
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ANTiCOAGULATiON iS AN iMPeRFeCT SCieNCe AND iS MORe 
COMPLeX iN NeONATeS AND YOUNG CHiLDReN
Unfractionated heparin (UFH) remains the anticoagulant of choice in pediatrics due to its short half-
life and potential for reversal by protamine sulfate. Recommendations for laboratory monitoring of 
UFH in children have been extrapolated from adult recommendations (1, 2). The activated partial 
thromboplastin time (aPTT) and anti-Xa assays, both routine anticoagulation monitoring tests, were 
developed based on the adult hemostatic system. Infants and children have differences in hemostasis 
compared with adults. Procoagulant proteins (Factors II, VII, IX, X, XI, and XII) and inhibitors of 
coagulation [Protein C, Protein S, antithrombin (AT), and α2 macroglobulin] are present in different 
quantities, and the fibrinolytic system is relatively downregulated in young children. These normal 
physiologic differences are termed “developmental hemostasis” (3–5).
A prospective study examining the use of UFH and monitoring by standard tests (aPTT and anti-
Xa) in neonatal and pediatric patients [not on extracorporeal life support (ECLS)] demonstrated 
poor correlation between UFH dose and both aPTT and anti-Xa (6). There was no correlation 
between aPTT and anti-Xa (6).
ANTiCOAGULATiON ON eCLS ADDS AN  
ADDiTiONAL LAYeR OF COMPLeXiTY
The ECLS circuit contains a large foreign surface area that causes a massive inflammatory response, 
which affects both the cellular and plasma components of blood. Shear stresses imposed by the ECLS 
circuit activate cellular blood elements, including platelets and leukocytes, as well as plasma ele-
ments, such as von Willebrand factor. The initiation of ECLS is associated with a significant increase 
TABLe 1 | UFH monitoring techniques.
Test Advantages Disadvantages
ACT •	 Inexpensive
•	 POC
•	 Whole blood test
•	 Measures end point of the 
clotting cascade, but does not 
solely tell you about UFH effect
aPTT •	 Accepted means of titrating 
anticoagulation therapy for both 
UFH and DTI
•	 POC now available
•	 High degree of intra- and 
interpatient variability 
especially in infants
•	 Less reliable in critical illness
Anti-Xa •	 Specific measure of UFH effect 
based on the ability of UFH 
to catalyze AT’s inhibition of 
factor Xa
•	 Better association with UFH 
dose
•	 Elevated plasma-
free hemoglobin and 
hyperbilirubinemia will 
underestimate UFH activity by 
anti-Xa
TEG/
ROTEM
•	 POC
•	 Whole blood test
•	 Provides information about both 
clot strength and fibrinolysis
•	 Limited availability
UFH, unfractionated heparin; POC, point-of-care; AT, antithrombin; DTI, direct thrombin 
inhibitor; TEG, thromboelastography; ROTEM, rotational thromboelastometry.
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in activation markers of the coagulation system suggesting a 
consumptive coagulopathy (7). This may further exacerbate the 
loss of both pro- and anticoagulant proteins.
It is impossible to completely control the interaction between 
blood and the biomaterials of the ECLS circuit; this results in a shift to 
a hypercoagulable state. Consequently, antithrombotic therapy is nec-
essary to prevent both circuit and patient thrombosis. Clinicians must 
balance the risk of bleeding complications with the need to maintain 
appropriate circuit flows and avoid thrombosis. A continuous UFH 
infusion is the default gold standard anticoagulant in ECLS; there are 
no large ECLS studies on any anticoagulants other than UFH. The 
optimal method to measure UFH efficacy on ECLS is unknown.
HePARiN iS AN iNDiReCT 
ANTiCOAGULANT
Heparin is a heterogeneous mixture of branched glycoaminogly-
cans in saccharide chains. UFH is a mixture of different molecular 
weights (ranging from 3000 to 30,000 kDa) and corresponding 
saccharide chain lengths (1). Heparin is an indirect anticoagulant 
in that it requires AT for its primary anticoagulant action, inhibi-
tion of both thrombin and FXa. UFH does not inhibit clot-bound 
thrombin or thrombin bound to the ECLS circuit. The anticoagu-
lant activity of UFH is variable for two reasons: (1) only one-third 
of an administered dose of UFH has the specific, active pentasac-
charide sequence that binds AT and (2) the anticoagulant profile 
of UFH is influenced by the chain length of the molecules (1).
Unfractionated heparin binds to AT via a unique glucosamine 
unit that contains a specific, active pentasaccharide sequence (1). 
The UFH/AT complex is responsible for the anticoagulant action 
of UFH by inhibition of Factors IIa (thrombin), Factors Xa, IXa, 
Xia, and XIIa. Once bound, the UFH/AT complex has 1000× 
the inhibitory effect compared with AT alone. The remaining 
two-third of the UFH dose, without the active pentasaccharide 
sequence, has minimal anticoagulant action at therapeutic doses 
and may, in fact, inhibit anticoagulation by binding to plasma 
proteins and activating platelets (1).
Heparin molecules are made up of different lengths of sac-
charide chains. UFH inhibits thrombin by AT binding via the 
high affinity pentasaccharide sequence as well as binding directly 
to the coagulation enzyme (1). Inhibition of FXa requires only the 
binding of AT to UFH via the specific pentasaccharide sequence. 
Thrombin (IIA) and Factor Xa are the most sensitive to inhibition 
by UFH/AT complex (1). However, only heparin molecules of 18 
or greater saccharide units are able to catalyze the interaction of 
both AT and thrombin. If the heparin saccharide chain is too 
short, it is unable to catalyze thrombin inhibition (1). As a result, 
there may be inhibition of FXa, but not of thrombin, which leads 
to variable anticoagulation. This heterogeneity makes monitoring 
of anticoagulation difficult.
STANDARD MONiTORiNG OF 
COAGULATiON iS iMPeRFeCT
Monitoring of coagulation is done in vitro, which eliminates the 
effects of the endothelium in vivo. This flaw is a major limitation 
in our understanding of how coagulation occurs in the patient. 
A second limitation is that the majority of our coagulation 
tests are plasma-based tests, partial functional measures of 
coagulation, and not whole blood tests that incorporate platelet 
function and assessment of clot strength. Table 1 summarizes 
the advantages and disadvantages of different UFH monitoring 
techniques.
Activated Clotting Time
The activated clotting time (ACT) is the only routine whole blood 
test performed on ECLS. ACT measures the time in seconds of 
whole blood to form fibrin clot after the addition of various 
coagulation activators. ACT does not measure clot strength. 
ACT was invented in the 1960s for cardiopulmonary bypass 
(CPB) and since then has been applied to various settings requir-
ing UFH anticoagulation. ACT results will vary based on many 
factors including platelet number and function, fibrinogen level, 
coagulation factor deficiencies, patient temperature, hemodilu-
tion, and technical factors (8). Hence, it does not represent, 
solely, UFH effect. Furthermore, different ACT machines yield 
different results either because of different coagulation activators 
or because they are measuring different end points. For exam-
ple, a common point-of-care (POC) ACT in the United States 
is the Hemochron System, either the Hemochron Response 
or the Hemochron Signature Elite. Both of these systems look 
at the time of whole blood to form clot, but measure this end 
point differently. The Hemochron Response System uses magnet 
technology; clot endpoint occurs with a specific displacement 
of the magnet. The Hemochron Signature Elite System detects 
clot formation by LED optical detectors that measure the speed 
of the blood sample. The instrument recognizes that a clot end-
point has been achieved when the movement decreases below a 
predetermined rate. Unfortunately, these systems cannot be used 
interchangeably (9).
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The I-STAT ACT is another POC ACT system. It is similar to 
traditional ACT tests except that the endpoint is indicated by the 
conversion of a thrombin product other than fibrinogen, and an 
electrochemical sensor is used to indicate this conversion. There 
is variability between different ACT monitoring systems, which 
makes comparisons between centers using different systems 
impossible (10).
Baird and colleagues retrospectively reviewed over 600 
pediatric ECMO patients and found only a modest correlation 
(r = 0.48) between ACT and UFH dose suggesting that ACT is 
not an accurate tool for monitoring UFH anticoagulation during 
pediatric ECMO (8). Other reports examining the correlation of 
UFH and ACT on ECLS provided mixed results varying from 
either no statistical correlation (11, 12) to a better correlation 
within individual patients (13).
Activated Partial Thromboplastin Time
Historically, dose monitoring of patients receiving UFH has been 
with the aPTT. The aPTT is a plasma-based test that measures the 
time from Factor XII activation to fibrin formation, after addition 
of calcium and a reagent. A prospective, adult study suggested 
that an aPTT between 1.5 and 2.5× normal was associated with a 
decreased risk of recurrent venous thromboembolism (2). Based 
on this adult study, the therapeutic range for the aPTT was set 
at 1.5–2.5× the patient’s pre-therapy baseline aPTT; however, 
this was validated neither in randomized controlled trials nor in 
children.
The use of aPTT for monitoring UFH is based on the assump-
tion that the patients’ baseline aPTT is comparable to normal 
controls; this assumption is critical for the linear relationship 
between UFH dose and aPTT. Unfortunately, the baseline aPTT 
in sick pediatric patients is very different from normal controls, 
which limits the utility of aPTT as a measure of UFH effect. 
Increased levels of non-specific acute phase reactants, Factor VIII, 
and fibrinogen often escalate in critically ill infants and children; 
increased levels of these proteins may falsely shorten the aPTT 
masking true UFH effect (6). As a result, aPTT demonstrates a 
high degree of intra- and interpatient variability, which resulted 
in increased number of blood tests for monitoring and frequent 
dose changes. Consequently, many clinical laboratories and clini-
cians have substituted the anti-Xa assay for UFH monitoring.
Anti-Xa Assay
The anti-Xa assay (alternatively called the heparin level) is a 
measure of UFH effect based on the ability of UFH to catalyze 
AT’s inhibition of Factor Xa. Anti-Xa is a plasma-based test 
that does not incorporate platelet function. The anti-Xa assay 
evaluates only one chemical reaction of the UFH–AT complex; 
it does not measure inhibition of thrombin. The anti-Xa is used 
as a surrogate measure of the overall anticoagulant activity of 
UFH. The same adult study that set the therapeutic aPTT at 
1.5–2.5× the patient’s baseline aPTT demonstrated that this 
therapeutic aPTT range corresponded to an anti-Xa activity of 
0.3–0.7 U/mL (2).
A number of single-center ECLS case series have found an 
improved association of anti-Xa with UFH dose as well as an 
associated decrease in blood sampling, decrease in blood product 
transfusion, and less complications, both thrombotic and hemor-
rhagic, while using anti-Xa as a part of UFH monitoring protocol 
during ECLS (13–17). The anti-Xa assay is a chromogenic assay, 
which can limit its utility in ECLS as the anti-Xa is falsely 
decreased when there is elevated plasma-free hemoglobin or 
bilirubin (18).
Newall and colleagues prospectively compared UFH concen-
tration via protamine titration and UFH effect via aPTT, anti-Xa, 
and thrombin clotting time (TCT) in a group of pediatric patients 
in the cardiac catheterization laboratory (19). Protamine titration 
is considered the gold standard of UFH concentration in plasma. 
Their results refute the pediatric recommendations for UFH 
management extrapolated from adult trials. Agreement between 
all measures of UFH effect and protamine titration was poor (19). 
They propose that the current recommendations for manage-
ment of UFH in pediatrics are inappropriate, which demands 
either different tests for monitoring UFH efficacy or alternative 
anticoagulants.
viscoelastic Testing
Viscoelastic tests [thromboelastography (TEG) and rotational 
thromboelastometry (ROTEM)] examine whole blood clot 
formation (coagulation) and dissolution (fibrinolysis). They are 
limited by static conditions (no flow) as well as the exclusion of 
vascular endothelium, but they are the only option available to 
evaluate clot strength. Additional benefits include POC testing 
that can be performed at the bedside and at the patient’s tempera-
ture. Additional information from viscoelastic testing includes 
time until initial fibrin formation, the kinetics of fibrin formation 
and clot development, the ultimate strength and stability of the 
fibrin clot, clot lysis, and platelet function (20). TEG and ROTEM 
are not yet widely available; only 43% of centers use viscoelastic 
tests as part of their routine anticoagulation monitoring on ECLS 
(21). There are limited reports documenting improved outcomes 
when TEG was incorporated into a bundled anticoagulation 
protocol (22).
ANTiTHROMBiN RePLACeMeNT
The optimal AT level for any patient receiving UFH anticoagula-
tion is unknown. In infants and children with escalating UFH 
requirements and/or clinically inadequate anticoagulant effect, 
relative AT deficiency may be a contributing factor. There is insuf-
ficient experience to provide evidence-based recommendations 
for AT concentrate use in children on ECLS.
If low AT levels are confirmed, AT replacement may be con-
sidered (23–26). AT concentrate and recombinant AT are now 
available and some centers will prophylactically replace it for AT 
activity <50–80% (<0.5–0.8 U/mL). Some centers will treat low 
AT levels only if there is evidence of reduced UFH effect based on 
low anti-Xa levels or minimal UFH effect on TEG kaolin versus 
TEG heparinase samples.
Of the ECLS programs that use AT replacement routinely as 
part of their anticoagulation protocol, most target levels from 
>50 to >100%. The use of AT concentrate is preferred over the 
administration of frozen plasma (FP) as giving standard bolus 
infusions of FP does not easily achieve adequate AT levels (may 
TABLe 2 | Comparison of UFH and bivalirudin.
Anticoagulant Mechanism of 
action
Dosing range Reversible Monitoring 
tests
Limitations
UFH Indirect – needs 
AT for maximal 
therapeutic effect
10–70 U/kg/h Protamine sulfate ACT, aPTT, 
anti-Xa, and 
TEG/ROTEM
•	 Only one-third of UFH molecules has pentasaccharide 
sequence that binds AT, which leads to variable 
anticoagulation
•	 Does not inhibit clot-bound thrombin
•	 Thrombocytopenia
Bivalirudin Direct thrombin 
inhibitor
0.3–1.2 mg/
kg/h
No specific antidote, but bleeding 
may be mitigated with factor VIIa
aPTT •	 Expect INR will increase
•	 Thrombosis with blood stasis (intracardiac and circuit)
UFH, unfractionated heparin; AT, antithrombin; TEG, thromboelastography; ROTEM, rotational thromboelastometry.
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need >20 mL/kg for FP to obtain clinical AT effect as standard 
plasma contains only 1 U/mL for AT).
The UFH infusion can be decreased (up to 50%) prior to AT 
replacement because of the potential for significant augmentation 
of UFH’s anticoagulant effect. ACT and anti-Xa should be checked 
30–60 min after AT administration to evaluate UFH effect.
ALTeRNATive ANTiCOAGULANTS
It is impossible to provide high quality evidence supporting the 
use of UFH alternatives on ECLS. However, there is increasing 
experience with alternative anticoagulants.
Direct Thrombin inhibitors
Direct thrombin inhibitors (DTIs) are not dependent on AT 
for their anticoagulant effect. They act directly to inhibit both 
circulating and clot-bound thrombin. DTIs are superior to UFH 
in their ability to inhibit clot-bound thrombin (27). Bivalirudin 
is a potentially attractive DTI as it is cleared mainly by intra-
vascular proteolytic degradation and less so by the kidneys 
(27). Bivalirudin may be used as the initial anticoagulant on 
ECLS or patients may be transitioned to bivalirudin in cases of 
heparin-induced thrombocytopenia (HIT) or heparin resist-
ance. Argatroban and lepirudin are other possible DTIs, but they 
rely on hepatic and renal clearance, respectively, which are organ 
systems often compromised on ECLS. Bivalirudin has a short 
half-life of 25–35 min, which is even shorter in children (27). 
Bleeding from bivalirudin is potentially reversible with activated 
Factor VII. Bivalirudin is approved for use as an anticoagulant in 
adult patients undergoing angioplasty. There is off-label experi-
ence using bivalirudin infusions in adult patients with HIT 
demonstrating successful anticoagulation with a target aPTT of 
1.5–2.5× normal (28).
There is minimal experience with bivalirudin in pediatric 
populations and even less in pediatric ECLS. Nagle and col-
leagues report a series of 12 children transitioned to bivalirudin 
because of UFH resistance, UFH failure, or HIT on ECLS (29). 
Their maintenance dose range of bivalirudin was very wide due 
to significant interpatient variability. They followed aPTT, but do 
not report their target range. Retrospective adult studies compar-
ing UFH and bivalirudin on ECLS demonstrated no difference in 
thromboembolic complications (30, 31).
There are evolving challenges with use of bivalirudin on 
ECLS. Bivalirudin does not work well when there is blood stasis, 
which is common on ECLS requiring the change of different 
circuit components and is worrisome for the development of 
intraventicular clot if the heart is not ejecting (32). Bivalirudin 
also falsely elevates INR (30). ACT does not appear to be useful 
in monitoring of bivalirudin, and while aPTT may be limited by 
poor linearity and reproducibility, it is the most common moni-
toring test. Most centers will initially target a lower therapeutic 
range (aPTT of 1.5–2.0× normal) and increase the target aPTT 
to 1.5–2.5× normal as necessary for optimal circuit mechanics. 
Table 2 compares UFH and bivalirudin.
New Oral Anticoagulants
Rivaroxaban is a highly specific inhibitor of Factor Xa, which 
prevents the formation of the thrombin burst by inhibiting 
coagulation at the point of amplification (33). There is limited 
in  vivo evidence in pediatrics. Oral factor-IIa inhibitors, such 
as dabigatran, are in use in adult patient for the prevention and 
treatment of thromboembolism. There is no data in adult ECLS. 
Their enteral administration and the paucity of pediatric studies 
will limit their use in pediatric ECLS.
Factor Xiia inhibitors
A new and alternative anticoagulation therapy based on an 
antibody to Factor XIIa was studied in an animal extracorporeal 
circuit model (34). This model demonstrated that a recombinant 
human FXIIa neutralizing antibody prevented fibrin deposition 
and thrombosis in the extracorporeal circuit and did not increase 
clinical bleeding.
PReveNTiON AND MANAGeMeNT OF 
BLeeDiNG AND THROMBOTiC 
COMPLiCATiONS
what is Considered Significant  
Bleeding on eCLS?
Both bleeding and thrombotic complications are associated 
with increased morbidity and mortality (35, 36). Complications 
reported in the ECLS literature are based on Extracorporeal 
Life Support Organization (ELSO) registry data that are non-
specific. A patient hemorrhagic complication is defined as one 
that requires transfusion or other intervention. We suggest that 
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clinically relevant bleeding be defined more specifically. Major 
bleeding may be defined as clinically overt bleeding associated 
with a hemoglobin drop of at least 20  g/L in a 24-h period; 
 bleeding that is retroperitoneal, pulmonary, or involves the 
central nervous system (CNS); bleeding >20 mL/kg over 24 h; or 
bleeding that requires surgical intervention (37). Minor bleeding 
may be defined as bleeding of 10–20 mL/kg over 24 h.
If there is excessive bleeding, particularly in postcardiotomy 
patients, holding the UFH for 4–6 h is reasonable. In some cir-
cumstances where bleeding is difficult to control, the UFH may be 
held up to 12 h or longer until bleeding is controlled.
Antifibrinolytic Therapy
There are no standardized dosing regimens for antifibrinolytic 
therapies on ECLS. These therapies are most commonly required 
to manage postoperative bleeding in the ECLS patient. Some 
centers use aminocaproic acid (Amicar) (38) or tranexamic acid 
(Cyklokapron) prophylactically in postcardiotomy patients, 
some use only prior to surgical intervention or when managing 
excessive bleeding, while others do not use at all. Amicar may 
be loaded (100  mg/kg IV bolus over 1  h) and then followed 
by continuous infusion of 25–33  mg/kg/h IV for at least 48  h. 
Tranexamic acid typically run as an infusion from 10 to 16 mg/
kg/h IV until bleeding subsides.
Activated Factor vii
There is conflicting data as to the safety and efficacy of activated 
Factor VII to manage refractory bleeding on ECLS (39–41). 
Activated Factor VIIa is considered for patients with severe, 
refractory hemorrhage only after the optimization of coagulation 
factors, fibrinogen, and platelets. Factor VIIa is usually given with 
platelets at a dose of 30–90 mcg/kg IV every 8 h for 3 doses.
Thrombotic Complications  
in the Patient and the Circuit
Circuit thrombosis becomes clinically relevant if it requires 
circuit intervention or is associated with severe hemolysis. 
Patient thromboses, particularly CNS infarcts, are likely under-
reported as not all patients receive neuroimaging after ECLS 
decannulation. Clinically relevant patient thrombosis, defined 
as an intracranial infarct demonstrated by neuroimaging after a 
change in a patient’s neurologic exam or screening test, may be 
the most practical definition of a patient thrombotic complica-
tion. Other patient thrombotic complications, such as renal or 
splenic infarcts, require imaging for diagnosis.
Heparin-induced Thrombocytopenia
Heparin-induced thrombocytopenia is an antibody-mediated 
event that results in paradoxical arterial and venous thrombosis. 
Since thrombocytopenia is common in critically ill patients and 
on ECLS, HIT is frequently suspected, but rarely diagnosed in 
pediatrics. The initial ELISA-based immunoassay that tests for 
the presence of antibodies against heparin-platelet factor 4 (PF4) 
conjugate is sensitive, but not specific (42). A serotonin release 
assay is typically performed as confirmatory testing when the 
immunoassay is positive (42).
Optimal Blood Product Replacement
There is a lack of studies that guide transfusion practices in 
ECLS patients. ELSO recommends that the patient is transfused 
to maintain a hemoglobin level of 140–150  g/L (43). A recent 
survey by Bembea and colleagues found variable thresholds for 
blood product transfusion (21). The majority of pediatric centers 
used a hematocrit of 35% with a range of 25–40% as a trigger for 
transfusion of red blood cells (RBCs) (21). The median platelet 
count that triggered platelet transfusion was 100,000 × 109/L with 
a range of 50,000–200,000 × 109/L (21).
Given the association of positive fluid balance and mortality in 
pediatric critical care as well as the concern about storage issues 
with RBC, some centers are re-examining their transfusion triggers. 
Fiser and colleagues recently examined the relationship between 
the transfusion of RBCs and changes in mixed venous saturation 
(SvO2) and cerebral regional tissue oxygenation, as measured by 
near infrared spectroscopy in patients supported with ECLS (44). 
The median hematocrit was 0.37. The majority of transfusions 
resulted in no significant change in either SvO2 or cerebral NIRS. 
There was no relationship between pre-transfusion hematocrit and 
the change in either SvO2 or cerebral NIRS suggesting that RBC 
transfusion did not significantly alter global tissue oxygenation (44).
Agerstrand and colleagues performed a retrospective study 
of 38 adults receiving ECLS for ARDS after initiation of a blood 
conservation protocol that included a transfusion trigger of 
hemoglobin <70 g/L, use of low dose anticoagulation targeting 
an aPTT of 40–60 s, and autotransfusion of circuit blood during 
decannulation (45). Only 24 patients (63%) required transfusion 
over a median ECLS run of 9 days (45). Twenty-eight patients 
(73.7%) survived to hospital discharge, which is comparable to 
the published literature. High survival rates with a hemoglobin 
transfusion trigger of 70 g/L suggest that a conservative transfu-
sion strategy may be applicable to this population (45).
CONCLUSiON
Unfractionated heparin anticoagulation on ECLS is extremely 
variable due to the heterogeneity of UFH molecules and UFH’s 
inability to inhibit clot-bound thrombin. As a result, it can be 
difficult to have a hemostatically balanced patient and a clean 
circuit. In addition, the ECLS patient population is critically ill, 
which may limit the use of standard anticoagulation monitoring 
tests. These tests are limited in that they are only partial functional 
measures of anticoagulation. Global measures of anticoagulation 
that use whole blood, incorporate platelets, and examine clot 
strength are becoming more widely available.
Bleeding and thrombotic complications are common in 
pediatric ECLS and are associated with increased mortality. 
Bivalirudin, a direct thrombin inhibitor, is a promising alterna-
tive anticoagulant as it avoids many of the limitations of UFH, but 
prospective rigorous studies are urgently needed. There remains 
a concern about increased risk of intracardiac thrombosis with 
bivalirudin if the heart is not ejecting. Additional studies are 
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required to challenge the current dogma and evaluate triggers for 
blood product replacement.
Interested readers should refer to the ELSO Anticoagulation 
Guidelines and Patient-Specific Protocols available on the ELSO 
website (http://ELSO.org) for further reading.
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